[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100631312":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":28,"centralContacts":32,"locations":39,"responsibleParty":69,"collaborators":71,"id":74,"slug":75,"hasResults":76,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":24,"eligibilityCriteria":80,"healthyVolunteers":76,"sex":81,"minAge":82,"maxAge":24,"enrollmentInfo":83,"targetDuration":24,"studyType":86,"phases":87,"briefSummary":89,"conditions":90,"keywords":93,"overallStatus":97,"whyStopped":24,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},{"fullName":5,"class":6},"University Hospital Ostrava","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Low anticoagulation dose of argatroban and enoxaparin during ECMO","EXPERIMENTAL","Study subjects in this group will receive low anticoagulation dose of argatroban and enoxaparin during ECMO.",[13],"Drug: Low anticoagulation dose of argatroban and enoxaparin during ECMO",{"label":15,"type":10,"description":16,"interventionNames":17},"Standard anticoagulation dose of argatroban and enoxaparin during ECMO","Study subjects in this group will receive standard anticoagulation dose of argatroban and enoxaparin during ECMO.",[18],"Drug: Standard anticoagulation dose of argatroban and enoxaparin during ECMO",[20,25],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Study subjects in this group will receive low anticoagulation dose of argatroban and enoxaparin during ECMO",[9],null,{"type":21,"name":15,"description":26,"armGroupLabels":27,"otherNames":24},"Study subjects in this group will receive standard anticoagulation dose of argatroban and enoxaparin during ECMO",[15],[29],{"name":30,"affiliation":5,"role":31},"Filip Burša, MD,Ph.D.,EDEC","PRINCIPAL_INVESTIGATOR",[33],{"name":34,"role":35,"phone":36,"phoneExt":37,"email":38},"Jiří Hynčica","CONTACT","+42059737","2587","jiri.hyncica@fno.cz",[40,54],{"facility":5,"status":24,"city":41,"state":42,"zip":43,"country":44,"countryCode":24,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Ostrava","Moravian-Silesian Region","708 52","Czechia",{"type":46,"coordinates":47},"Point",[48,49],18.28204,49.83465,{"lat":49,"lon":48},[52,53],{"name":34,"role":35,"phone":36,"phoneExt":37,"email":38},{"name":30,"role":31,"phone":24,"phoneExt":24,"email":24},{"facility":55,"status":24,"city":56,"state":24,"zip":57,"country":44,"countryCode":24,"cosmosGeoPoint":58,"geoPoint":62,"contacts":63},"University Hospital Motol","Prague","150 00",{"type":46,"coordinates":59},[60,61],14.42076,50.08804,{"lat":61,"lon":60},[64,68],{"name":65,"role":35,"phone":66,"phoneExt":24,"email":67},"Jaromír Vajter, MD,Ph.D.","+420603512475","jaromir.vajter@fnmotol.cz",{"name":65,"role":31,"phone":24,"phoneExt":24,"email":24},{"type":70,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR",[72],{"name":73,"class":6},"University Hospital, Motol","100631312","phase-2-safety-and-efficacy-of-low-dose-anticoagulation-with-argatroban-and-enoxaparin-on-ecmo-100631312",false,"NCT07499037","Safety and Efficacy of Low-dose Anticoagulation With Argatroban and Enoxaparin on ECMO","Low-dose Versus Standard-dose Anticoagulation With Argatroban and Enoxaparin During Extracorporeal Membrane Oxygenation Controlled by Anti-IIa and An-ti-Xa, Respectively","Inclusion Criteria:\n\n* ECMO support with anticoagulation using argatroban\u002Fenoxaparin\n* Age ≥ 18 years\n* Obtaining informed consent in accordance with the procedure specified in the protocol\n\nExclusion Criteria:\n\n* Enrolment in the lung transplant program at Motol University Hospital\n* Known hypersensitivity to the components of the evaluated products\n* Allergic reaction to the active ingredients of the evaluated products\n* Pregnancy and breastfeeding","ALL","18 Years",{"count":84,"type":85},200,"ESTIMATED","INTERVENTIONAL",[88],"PHASE2","The standard and most common therapy is anticoagulation with heparin according to activated partial thromboplastin time (aPTT) during extracorporeal membrane oxygenation (ECMO) support. The study will focus on evaluating the efficacy and safety of new anticoagulants on ECMO, namely argatroban and enoxaparin in lower doses controlled according to targeted antiIIa and antiXa markers.",[91,92],"Pneumonia","Heart Failure",[94,91,95,96],"ECMO","Heart failure","Anticoagulation","NOT_YET_RECRUITING","2026-03-27",{"date":100,"type":101},"2026-04-02","ACTUAL",{"date":103,"type":85},"2027-01",{"date":105,"type":85},"2029-12",{"name":5,"class":6},2]